Abstract
Neurotrophins (NTs) and their receptors, TrKs and p75NTR, have been shown to regulate proliferation and apoptosis of neoplastic cells. Pharmacological TrK blockade is considered a valuable target in cancer therapy, and several TrK inhibitors are under investigation. However, only a few of them have reached the stage of clinical development. Myosarcomas are aggressive cancers, which secrete NGF and respond poorly to available chemotherapies. Our previous work has shown that these cancers, characterized by autocrine activation of TrKA by NGF, which promotes cancer growth and survival, are highly susceptible to TrK blockade, both in vitro and in vivo. The same pattern has also been described in prostatic carcinoma. The present report characterizes for the first time the anti-proliferative and pro-apoptotic effects of the oxindole TrK inhibitor GW441756, in a panel of human myosarcomas and prostatic adenocarcinoma cell lines. Furthermore, we provide novel evidence that, in myosarcomas, characterized by a high-TrK/low-p75NTR phenotype, GW441756 upregulates p75NTR receptor expression, leading to apoptosis via caspase-3 activation. Altogether, our data expand the knowledge of the anti-neoplastic and pro-apoptotic mechanisms of GW441756, and of TrK inhibitors in general, lending further support to the therapeutic potential of TrK blockade in clinical oncology.
Keywords: Apoptosis, Cancer, GW441756, Neurotrophins, p75NTR, myosarcoma, TrKs, Trk inhibitors
Current Signal Transduction Therapy
Title:Antiproliferative and Proapoptotic Effects of the TrK-inhibitor GW441756 in Human Myosarcomas and Prostatic Carcinoma
Volume: 8 Issue: 1
Author(s): Anna M. Stabile, Claudia Montagnoli, Alessandra Pistilli, Maria Grazia Rambotti, Grazia Pula and Mario Rende
Affiliation:
Keywords: Apoptosis, Cancer, GW441756, Neurotrophins, p75NTR, myosarcoma, TrKs, Trk inhibitors
Abstract: Neurotrophins (NTs) and their receptors, TrKs and p75NTR, have been shown to regulate proliferation and apoptosis of neoplastic cells. Pharmacological TrK blockade is considered a valuable target in cancer therapy, and several TrK inhibitors are under investigation. However, only a few of them have reached the stage of clinical development. Myosarcomas are aggressive cancers, which secrete NGF and respond poorly to available chemotherapies. Our previous work has shown that these cancers, characterized by autocrine activation of TrKA by NGF, which promotes cancer growth and survival, are highly susceptible to TrK blockade, both in vitro and in vivo. The same pattern has also been described in prostatic carcinoma. The present report characterizes for the first time the anti-proliferative and pro-apoptotic effects of the oxindole TrK inhibitor GW441756, in a panel of human myosarcomas and prostatic adenocarcinoma cell lines. Furthermore, we provide novel evidence that, in myosarcomas, characterized by a high-TrK/low-p75NTR phenotype, GW441756 upregulates p75NTR receptor expression, leading to apoptosis via caspase-3 activation. Altogether, our data expand the knowledge of the anti-neoplastic and pro-apoptotic mechanisms of GW441756, and of TrK inhibitors in general, lending further support to the therapeutic potential of TrK blockade in clinical oncology.
Export Options
About this article
Cite this article as:
M. Stabile Anna, Montagnoli Claudia, Pistilli Alessandra, Grazia Rambotti Maria, Pula Grazia and Rende Mario, Antiproliferative and Proapoptotic Effects of the TrK-inhibitor GW441756 in Human Myosarcomas and Prostatic Carcinoma, Current Signal Transduction Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574362411308010010
DOI https://dx.doi.org/10.2174/1574362411308010010 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets LGI1 Affects Survival of Neuroblastoma Cells by Inhibiting Signalling through Phosphoinositide 3-Kinase
Current Signal Transduction Therapy Intracompartmental Delivery of CNTF as Therapy for Huntingtons Disease and Retinitis Pigmentosa
Current Gene Therapy Current Trends in Virtual High Throughput Screening Using Ligand-Based and Structure-Based Methods
Combinatorial Chemistry & High Throughput Screening Getting Rid of Intracellular Aβ - Loss of Cellular Degradation Leads to Transfer Between Connected Neurons
Current Pharmaceutical Design Intra-arterial Instillation of a Nociceptive Agent Modulates Cardiorespiratory Parameters Involving 5-HT3 and TRPV1 Receptors in Anesthetized Rats
Cardiovascular & Hematological Disorders-Drug Targets The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Current Topics in Medicinal Chemistry Anticancer Evaluation of 3,4,5,4'-trans-tetramethoxystilbene (DMU-212) and Its Analogs Against an Extensive Panel of Human Tumor Cell Lines
Letters in Drug Design & Discovery One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Potential Role of Acrolein in Neurodegeneration and in Alzheimers Disease
Current Molecular Pharmacology Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor
Current Drug Targets Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity
Current Drug Metabolism Biocompatible Micelles Based on Squalene Portions Linked to PEGylated Polyaspartamide as Potential Colloidal Drug Carriers
Current Nanoscience A Comparative Study of Synthetic Approaches Towards Total Synthesis of Mandelalide A, An Anti-Lung Cancer Metabolite From Lissoclinum Ascidian
Current Organic Chemistry Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Evolution of the Strategies for Screening and Identifying Human Tumor Antigens
Current Protein & Peptide Science Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Edelfosine in Membrane Environment - the Langmuir Monolayer Studies
Anti-Cancer Agents in Medicinal Chemistry